DoW Lung Cancer Idea Development Award
Supports early-stage, high-risk/high-reward lung cancer research projects that address at least one FY26 LCRP area of emphasis, with a separate New Investigator category and required preliminary data.
⚑ Preliminary data required; data need not come from lung cancer studies. · Has a New Investigator category for early-career faculty. · Must address at least one FY26 LCRP area of emphasis. · Award ceiling listed as $0 in notice; verify funding details in full solicitation.
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds basic research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds basic research |
| Tom Love Innovation Hub | 15 none | deep-tech content; no commercialization signal |
Description
Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis.
Distinctive Features: This FY26 LCRP IDA mechanism has a New Investigator category that is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.
Apply
View on Grants.gov → CONTACT: Danielle Reckley Grantor <help@eBRAP.org>